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Dipyridamole inhibits PDGF- and bFGF-induced vascular
smooth muscle cell proliferation
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Dipyridamole inhibits PDGF- and bFGF-induced vascular smooth
muscle cell proliferation. Dipyridamole is the only pharmacologic agent
demonstrated to reduce polytetrafluoroethylene (PTFE) graft occlusion in
hemodialysis patients. However, the mechanism of action of dipyridamole
in preventing graft occlusion is unknown. The purpose of this study was to
examine the direct effects of dipyridamole on both platelet-derived growth
factor (PDGF) and basic fibroblast growth factor (bFGF)-induced vascu-
lar smooth muscle cell (VSMC) proliferation. Human aortic smooth
muscle cells were grown to confluence in 96 well plates. A total of 5 ><
106 molar dipyridamole, PDGF 10 ng/ml, or bFGF 10 nglml were added
to appropriate wells at the start of each experiment. Cell proliferation at
48 hours was determined using tritiated thymidine uptake. Intracellular
cyclic AMP (cAMP) was measured using a competitive enzyme immuno-
assay. Treatment of VSMC with 5 j.M dipyridamole dramatically reduced
basal proliferation rates compared to controls [5229 1131 counts per
minute (CPM) versus 387 68 CPM, P < 0.001]. Treatment with
dipyridamole also reduced PDGF-stimulated VSMC proliferation
(7311 1655 CPM vs. 593 110 CPM, P < 0.001) as well as the response
to bFGF (5632 1270 CPM vs. 310 31 CPM, P < 0.001). Treatment of
VSMC with either 5 or 20 jM dipyridamole did not change intracellular
cAMP levels. Furthermore, the addition of dibutyryl cAMP to VSMC
demonstrated only a modest inhibitory effect on proliferation. We con-
clude that dipyridamole inhibits both PDGF- and bFGF-stimulated
VSMC proliferation. The effects of dipyridamole on VSMC proliferation
do not appear to be entirely mediated by changes in intracellular cAMP
concentrations. The direct effect of dipyridamole on VSMC proliferation
may account for its efficacy in reducing PTFE graft thrombosis in
hemodialysis patients.
Graft failure after hemodialysis access surgery continues to
result in considerable morbidity and mortality [1, 2]. It has
recently been estimated that hospitalization costs related to
vascular access morbidity for Medicare patients in the United
States will approach 1 billion dollars in 1995 and result in 90,000
hospitalizations [21, At least 75 to 80% of hemodialysis graft
failures occur secondary to an exuberant hyperplastic intimal
response of the vascular wall, frequently referred to as myointimal
or neointimal hyperplasia [3—8].
While the the autologous brachio-cephalic (Brescia-Cimino)
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fistula remains the long-term hemodialysis access of choice,
expanded polytetrafluoroethylene (ePTFE) arteriovenous grafts
are used with increasing frequency. In 1990, 83% of all permanent
vascular accesses placed in end-stage renal disease (ESRD)
patients in the United States were PTFE grafts [9]. The increased
use of ePTFE grafts has been attributed to an increased propor-
tion of elderly, female and diabetic patients, all of whom tend to
have relatively poor vasculature for the formation of autologous
fistulae.
Despite extensive use of PTFE grafts for permanent hemodi-
alysis access, there is to date only one large prospective random-
ized, placebo-controlled clinical trial examining pharmacologic
approaches to decrease the rate of PTFE graft thrombosis in this
patient population [10]. The results of this study demonstrated a
significant decrease in the rate of thrombosis in patients taking
dipyridamole (relative risk 0.35) and a trend toward a higher rate
of thrombosis in patients taking aspirin.
Although the results of this clinical study clearly demonstrated
a beneficial role for dipyridamole in preventing ePTFE thrombo-
sis, this study did not establish a mechanism of action by which
dipyridamole exerted a beneficial effect. Since the beneficial
effect of dipyridamole occurred more than six months after PTFE
placement, it is likely that the observed beneficial effect was due
to diminishing the development of myointimal hyperplasia and
consequent stenosis in the venous limb of these grafts. We
therefore hypothesized that dipyridamole may have inhibited
vascular smooth muscle cell (VSMC) migration and proliferation.
Based upon the known role of both basic fibroblast growth factor
(bFGF) and platelet-derived growth factor (PDGF) as mitogens
in the development of myointimal hyperplasia, we have investi-
gated the effect of dipyridamole on bFGF and PDGF-induced
cultured vascular smooth muscle cell proliferation.
METHODS
Materials
Human aortic smooth muscle cells (HASMC) and smooth
muscle basal media (SmBM) were purchased from Clonetics, Inc.
(San Diego, CA, USA). Human recombinant PDGF-AB was
purchased from Fisher Scientific (Medford, MA, USA). Dibutyryl
cyclic AMP and dipyridamole were purchased from Sigma (St.
Louis, MO, USA). The bFGF was purchased from R&D Systems
(Minneapolis, MN, USA). Cyclic AMP enzyme immunoassay kits
were purchased from Amersham Life Sciences (Arlington
Heights, IL, USA) and the Pierce BCA' protein assay was
purchased from Pierce (Rockford, IL, USA). The MU Cell
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Proliferation kit containing 3-[4.5-dimethylthiazol-2-yL}-2,5-di-
phenyl tetrazolium bromide was purchased from Boehringer
Mannheim Biochemica (Indianapolis, IN, USA).
Proliferation assay
Human aortic smooth muscle cells (HASMC) were seeded at
3.2 x iO cells per well in a 96 well plate in SmBM containing 5%
fetal bovine serum, 1% antibiotic/antimycotic solution. 5.0 X iO
molar stock solution of dipyridamole was prepared in water
acidified to a ph of 2.8. The dipryridamole was added to a final
concentration of 5 >< 1O_6 molar in SmBM with 5% fetal bovine
serum and added to the appropriate wells at the beginning of the
experiment. PDGF-AB and bFGF were diluted in media and 10
or 20 nglml was added at the beginning of each experiment. In
experiments testing the effect of cAMP analogues on prolifera-
tion, dibutyryl cAMP was added at the beginning of each exper-
iment at concentrations of 5 /.LM, 50 /.LM and 100 jIM. The HASMC
were incubated at 37°C in a 5% CO2 incubator during the
experiments. The cells were incubated with tritiated thymidine (1
jICi/well) for 24 hours before harvest. At 48 hours the cells were
washed with phosphate buffered saline and incubated with trypsin
for 10 minutes. A SCATRON cell harvester (Sterling, VA, USA)
was used to capture DNA residue on filter discs. The filter disks
were placed in a scintillation vial with scintillation fluid and
counted on a beta counter. The data are displayed as counts per
minute and reflect new DNA synthesis and cellular proliferation.
For assays investigating the reversibility of dipyridamole effects,
the method was the same as the proliferation assays except that
the HASMC were seeded in five 96-well plates, and at 48 hours
after the cells were treated with dipyridamole and one plate was
harvested, while the rest of the plates were re-fed with fresh
media. Plates were harvested at 72, 96, 120 and 144 hours and
tritiated thymidine uptake was quantified using a beta counter.
MTT viability assay
Cells were seeded in 96 well plates in 5% FBS in SmBM. After
48 hours the cells were re-fed with 5% FBS in SmBM and 5 jIM
dipyridamole was added to the cells in the presence or the absence
of 20 ng/ml PDGF. After incubating the cells at 37°C for 48 hours
the cells were treated with the MTT labeling solution and four
hours later solubilized in 10% sodium dodecyl sulfate in 0.01 M
HCI. The cells were then allowed to incubate overnight and the
absorbance was measured on a plate reader at 570 nM with the
reference wavelength at 650 n. Relative cell number was deter-
mined by plotting absorhance versus sample.
Trypan blue exclusion
Human aortic smooth muscle cells (HASMC) were seeded in
100 mm dishes at 6 >< iO cells per dish in 5% FBS in SmBM.
After 48 hours the cells were re-fed with 5% FBS in SmBM and
treated with 5 jIM dipyridamole or 5% FBS as a control. The cells
were washed 2x in PBS and incubated with trypsin and counted
on a hemocytometer 24 and 48 hours after treatment with
dipyridamole.
Adenosine 3',5'-cyclic phosphate enzyme immunoassay
The HASMC were seeded in Corning 6 well plates at a density
of 6.0 x io cells per well in SmBM containing 5% FBS. After 48
hours the cells were treated with vehicle (water pH 2.8), 5 jIM
dipyridamole, 20 jIM dipyridamole, 10 ng/ml PDGF, 10 ng/ml
Fig. 1. Effect of dipyridamole on basal and platelet-derived growth factor
(PDGF)-stimulated vascular smooth muscle cell (VSMC) proliferation.
< 0.001 vs. control. N = 6 experiments.
PDGF+5 tLM dipyridamole, or 10 jIM forskolin. After two, four,
and six hours the cells were washed in ice cold buffer containing
50 mM Tris, 4 mM EDTA at a pH of 7.4. A total of 400 J.Ld of this
buffer was added to each well and the cells were scraped and
transferred to a 1.5 ml Eppendorf tube. Two wells were used per
condition. The samples were boiled for three minutes and then
spun at 10,000 RPM for 10 minutes. The supernatants were
placed in clean Eppendorf tubes and frozen at —70°C. The
amount cAMP was measured using a competitive enzyme immu-
noassay. Each sample was normalized for protein content using
the Pierce BCA assay.
Statistical analysis
Changes in vascular smooth muscle cell proliferation or cAMP
levels between experimental groups were analyzed using art
analysis of variance (ANOVA) with condition, time and experi-
ment as variables. A Bonferroni correction was utilized to account
for multiple comparisons. Each experiment represents analysis of
at least 12 data points per experimental condition.
RESULTS
Dipyridamole inhibits basal and platelet-derived growth factor-
stimulated vascular smooth muscle cell proliferation
Treatment of VSMC with 5 x i0 molar dipyridamole dra-
matically reduced basal proliferation rates relative to controls
[5229 1131 counts per minute (CPM) vs. 387 68 CPM, P <
0.001, Fig. 1]. As expected, the addition of PDGF 10 ng/ml
resulted in an increase in VSMC proliferation above control
values (7311 1655 CPM vs. 5229 1131 CPM, P < 0.001).
Treatment of VSMC with dipyridamole significantly reduced the
proliferative response to PDGF (593 110 CPM) compared to
PDGF-stimulated VSMC cultures or to basal proliferative cul-
tures (P < 0.001 in both cases). To ensure that the effects of
dipyridamole on PDGF-stimulated VSMC proliferation were not
related to the presence of 5% fetal bovine serum in the cuture
media, we performed experiments using 0.5% fetal bovine serum
with similar results (data not shown).
Dipyridamole inhibits basic fibroblast growth factor-stimulated
vascular smooth muscle cell proliferation
To examine whether the profound inhibitory effect of dipyrid-
amole on PDGF stimulated VSMC proliferation was due to a
specific inhibition of PDGF stimulation, we also examined the
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Fig. 2. Effect of basic fibroblast growth factor (bFGF) on basal- and
vascular smooth muscle cell (VSMC) proliferation. P < 0.001 vs. control.
N = 3 experiments.
effect of dipyridamole on bFGF-induced VSMC proliferation
(Fig. 2). As in the previous experiments, the addition of 5 J.LM
dipyridamole profoundly inhibited basal proliferative rates of
vascular smooth muscle cells in culture (3373 199 CPM vs.
249 32 CPM, P < 0.001). The addition of bFGF as expected
resulted in an increase over basal VSMC proliferative rates
(5632 1270 CPM vs. 3373 199 CPM, P < 0.001). The addition
of dipyridamole also resulted in a profound inhibition of bFGF-
induced VSMC proliferation (5632 1270 CPM vs. 310 31
CPM, P < 0.001). These studies demonstrate that the effects of
dipyridamole on VSMC proliferation are not agonist-specific, but
affect the response to both PDGF and bFGF.
Time course of dipyridamole inhibition of platelet-derived
growth factor-stimulated vascular smooth muscle cell
proliferation
To gain insight into the possible mechanisms by which dipyrid-
amole inhibits PDGF-stimulated VSMC proliferation, we con-
ducted experiments in which 5 .tM dipyridamole was added to
cultured VSMC at either six hours or 24 hours after the addition
of PDGF (Fig. 3). As in previous experiments, the addition of 5
I.LM dipyridamole to cultured VSMC at the time of PDGF
stimulation resulted in profound inhibition of VSMC proliferation
at 48 hours (590 33 CPM at 48 hr vs. 14,345 927 CPM, P <
0.001). Similar levels of inhibition of VSMC proliferation were
noted if dipyridamole was added six hours after PDGF stimula-
tion (662 58 CPM, P < 0.001) or 24 hours after PDGF
stimulation (635 53 CPM, P < 0.001). These results indicate
that the inhibitory effects of dipyridamole on growth-factor-
induced VSMC proliferation even if dipyridamole is added after
the initial stimulatory event.
Reversability of platelet-derived growth factor-stimulated
vascular smooth muscle cell proliferation by dipyridamole
To insure that the effects of 5 iM dipyridamole on basal-,
PDGF- and bFGF-stimulated VSMC proliferation were due to a
pharmacologic and not a toxic effect on vascular smooth muscle
cells, we conducted experiments designed to test for dipyridamole
toxicity. In these experiments, after PDGF-induced VSMC stim-
ulation in the presence of 5 .tM dipyridamole for 48 hours, all cells
were washed and new growth media as well as PDGF were added.
VSMC proliferation was measured by tritiated thymidine uptake
every 24 hours out to 144 hours (Fig. 4).
In control cultures without the addition of PDGF, there were
Fig. 3. Time course of the inhibitory effect of dipyridamole on vascular
smooth muscle cell (VSMC) proliferation. *P < 0.001 vs. platelet-derived
growth factor (PDGF). N = 3 experiments.
no significant differences in VSMC proliferation rates over time
from 48 hours to 144 hours (4119 1196 CPM at 48 hr, 4071
1200 CPM at 72 hr, 2714 1201 CPM at 96 hr, 3765 1776 CPM
at 120 hr, and 2913 980 CPM at 144 hr). As noted in the
previous set of experiments, the addition of 5 !.tM of dipyridamole
resulted in a profound inhibition of VSMC proliferation at 48
hours (301 98 CPM vs. 4119 1196 CPM, P < 0.001).
However, after cell washing and replacement with fresh growth
media not containing dipyridamole, VSMC proliferation had
increased to 2653 1377 CPM by 72 hours after removal of
dipyridamole. These results indicated that the inhibitory effects of
dipyridamole on basal VSMC proliferation are reversible after
removal of dipyridamole from the culture media and replacement
of fresh culture media.
In the same set of experiments, PDGF stimulated VSMC
consistently showed greater proliferation than control samples at
each time point (8322 605 CPM vs. 4119 1196 CPM, P <
0.001 at 48 hr, 11,924 101 CPM vs. 4071 1200 CPM, P < 0.001
at 72 hr, 10,530 2443 CPM vs. 2714 1201 CPM, P < 0.001 at
96 hr, 8373 2500 CPM vs. 3765 1776 CPM, P < 0.001 at 120
hr, 4039 825 CPM vs. 2913 980 CPM, P < 0.001 at 144 hr).
As in previous experiments, the addition of 5 /LM dipyridamole
had a profound inhibitory effect on PDGF stimulated VSMC
proliferation at 48 hours (656 178 CPM vs. 8322 605 CPM).
The removal of dipyridamole from the media and supplementa-
tion with fresh growth media resulted in a dramatic increase in
VSMC proliferation in the previously dipyridamole treated cells
by 72 hours (4123 1416 CPM vs. 656 178 CPM, P < 0.001).
By 72 hours, VSMC proliferation in response to PDGF was
similar whether or not cells had previously been treated with
dipyridamole (7336 3275 CPM vs. 8373 2500 CPM, P = NS).
These experiments demonstrated that the effects of dipyridamole
on PDGF-stimulated VSMC proliferation are reversible over
time. To confirm that the effects of dipyridamole in inhibiting
basal-, PDGF- and bFGF-stimulated VSMC proliferation are not
due to a toxic effect, we also examined cell viability at 48 hours by
both tiypan blue exclusion and by the MIT assay. In all cases
there were no differences in cell viability between dipyridamole-
treated and non-dipyridamole-treated VSMC cultures (data not
shown).
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Dibutyryl adenosine 3',5'-cyclic phosphate inhibits vascular
smooth muscle proliferation
Dipyridamoic at high concentrations is known to function as a
phosphodiesterase inhibitor, thereby increasing intracellular cy-
clic AMP (cAMP) levels. We therefore investigated whether
administration of dibutytyl cAMP to vascular smooth muscle cells
in culture could reproduce the growth inhibitory effects that we
had observed (Fig. 5). In these experiments, the addition of
dibutyryl cAMP at either 50 jiM or 100 jiM concentrations
demonstrated a modest inhibitory effect on vascular smooth
muscle cell proliferation in control media (5107 138 CPM vs.
6896 270 CPM for 50 jiM cAMP, P < 0.001, 4662 2779 CPM
vs. 6896 270 CPM for 100 JLM cyclic AMP, P < 0.05). In these
experiments, 5 jiM dibutyryl cyclic AMP had no effect on VSMC
proliferation (6574 634 CPM vs. 6896 270 CPM). The
addition of dibutyryl cAMP also had an inhibitory effect on
PDGF-stimulated VSMC proliferation (Fig. 6).
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Fig. 6. Effect of dibytyryl cyclic AMP (dbc AMP) on platelet-derived
growth factor (PDGF)-stimulated vascular smooth muscle cell (VSMC)
proliferation. *p < 0.00 1 vs. PDGF control. N = 3 experiments.
Dipyridamole and vascular smooth muscle adenosine 3',5'-
cyclic phosphate levels
To confirm that the inhibitory effects of dipyridamole on
VSMC proliferation were not entirely due to an increase in
intracellular cAMP levels, we measured cAMP levels by enzyme
immuno assay after incubation of VSMC with either dipyridamole
(5 and 20 jiM), PDGF, or PDGF plus 5 /.LM dipyridamole. In these
experiments, forskolin, a known adenylate cyclase stimulator, was
used as a positive control (Fig. 7). The addition of either 5 jiM or
20 jiM dipyridamole did not result in a significant change in
VSMC cAMP levels at two, four or six hours after incubation. In
contrast, the addition of PDGF 10 ng/ml did result in a slight but
statistically significant increase in VSMC cAMP levels at two
hours (38.9 13 fmol/j.tg protein vs. 22.3 7.8 fmol/jig protein at
2 hr, P = 0.01) as well as at four hours (37.2 10.2 fmol/jig
protein vs. 16.2 4.1 fmolljig protein, P = 0.05). The addition of
5 jiM dipridamole to PDGF-stimulated VSMC did not change
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cAMP levels versus PDGF alone at any time point. The addition
of forskolin, as expected, resulted in a significant increase in cyclic
AMP concentrations in VSMC at all time points (Fig. 7).
DISCUSSION
Russell Ross and others have formulated a "response to injuly"
hypothesis to explain the development of myointimal hyperplasia,
which shares common characteristics with atherosclerosis [11]. A
prominent role in this hypothesis is given to the secretion of
platelet-derived growth factor (PDGF) by platelets adherent to
the subendothelium. Platelet-derived growth factor has been
demonstrated both to increase smooth muscle cell proliferation as
well as to promote migration of smooth muscle cells to the intima
[12, 13]. The administration of PDGF increases myointimal
hyperplasia formation, while antibodies to PDGF reduce myointi-
mal hyperplasia in animal models [14].
In addition to the postulated role of PDGF, recent studies have
identified other growth factors as critical in the development of
the intimal hyperplastic lesion. In particular, basic fibroblast
growth factor (bFGF) is critical for stimulating the first wave of
smooth muscle cell replication. Basic fibroblast growth factor is
released from injured vascular smooth muscle cells to an extra-
cellular pool where it can bind to both high and low affinity
receptors. Infusion of bFGF causes a dramatic increase in vascu-
lar smooth muscle cell replication, and daily infusion of bFGF
leads to a striking increase in intimal hyperplastic lesions in
animal models [15—17].
We have demonstrated that pre-treatment of cultured human
aortic smooth muscle cells (with dipyridamole profoundly inhibits
the proliferative response to both PDGF and bFGF as well as to
growth media. The effects of dipyridamole on VSMC prolifera-
tion are reversable over time, demonstrating that these effects are
pharmacological and not due to a toxic effect. The concentration
of dipyridamole used in these experiments (5 /.LM) is comparable
to plasma concentrations (2 to 6 .LM) obtained after oral admin-
istration of conventional doses (100 to 400 mg per day) [18, 19].
These studies strongly suggest that inhibition of vascular smooth
cell proliferation may be the mechanism by which dipyridamole
suppresses the development of myointimal hyperplasia in clinical
studies of PTFE hemodialysis grafts.
A number of experimental studies have suggested that therapy
with aspirin and dipyridamole reduces the development of my-
ointimal hyperplasia. Combined treatment with aspirin and dipy-
ridamole reduced intimal hyperplasia of aortic PTFE and iliac
vein grafts in a non-human primate model [20]. A similar reduc-
tion of intimal hyperplasia was noted in a canine model of
saphenous vein coronary artery bypass grafts [21]. Oblath et al
found that a combination of aspirin and dipyridamole virtually
eliminated myointimal hyperplasia formation in canine femoral
PTFE and Dacron grafts, while control grafts had a 40% throm-
bosis rate and a 35% intimal hyperplasia rate [22]. Singh et al
demonstrated that local delivery of dipyridamole reduced both
vascular smooth muscle cell replication and inhibited intimal
thickening in the arterial circulation after balloon injury [23]. This
study is particularly notable in that the effects on vascular smooth
muscle cell proliferation could clearly be attributed to dipyridam-
ole and not to combined antithrombotic therapy with aspirin as in
most other studies.
Similarly, Hess, Mietaschk and Deichsel reported a study in
which 240 patients with peripheral vascular disease were ran-
domly assigned to receive either aspirin plus dipyridamole, aspirin
alone or placebo for two years [24]. Blinded comparison of
angiograms obtained before treatment and at the conclusion of
the study were made. In the paired comparisons of the entire
study group, aspirin plus dipyridamole was significantly better
than either the placebo or the aspirin alone groups.
While dipyridamole can reduce the development of myointinial
hyperplasia, a mechanism for its action has never been firmly
established [25]. Dipyridamole has been suggested to act as an
antiplatelet and antithrombotic drug by several mechanisms [26,
27]. Dipyridamole is a phosphodiesterase inhibitor, increasing
intracellular cAMP and inhibiting platelet activation [28]. Dipy-
ridamole also inhibits adenosine reuptake by erythrocytes, also
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potentiating the inhibitory effects of adenosine on platelet func-
tion. Dipyridamole has been shown to have anti-adhesive effects
between platelets and endothelium by enhancing prostacyclin
biosynthesis [29] and 13-hydroxyoctadecadienoic acid production
by endothelium [30].
Despite these reported antiplatelet mechanisms, the relevance
of these pharmacologic properties to the action of dipyridamole
after oral doses in humans has been questioned [25, 261. Several
groups have not been able to demonstrate a correlation between
inhibition of platelet aggregation and the level of intraplatelet
cAMP with dipyridamole [31, 32]. Boeynaems, et al, reported that
dipyridamole in concentrations up to 100 j.LM did not induce the
release of prostacyclin either from rabbit aortic rings or from
endothelial cells cultured from bovine aorta [33]. Only the effects
of dipyridamole on inhibiting the uptake of adenosine by eryth-
rocytes and endothelial cells can be demonstrated at therapeutic
concentrations [34—36].
Other studies have questioned the relevance of dipyridamole as
a platelet inhibitor, as well as the role of platelets in the
development of intimal hyperplasia. It has been difficult to
demonstrate a diminished platelet aggregation response & vivo in
patients receiving dipyridamole [18, 37], and concentrations of
dipyridamole much greater than therapeutic levels are required to
influence platelet aggregation in vitro [37—39]. Dipyridamole has
also not been demonstrated to decrease platelet deposition on
PTFE grafts [40]. Furthermore, since intimal proliferation of
smooth muscle cells in PTFE grafts can occur underneath an
intact end othelium without platelet adherence [41], it is likely that
intimal cells rather than platelets provide the growth factors that
regulate intimal proliferative lesions under these clinical circum-
stances. Therefore, it seems unlikely that dipyridamole is effective
in vivo in reducing PTFE graft thrombosis in hemodialysis pa-
tients via an antiplatelet mechanism.
In addition to the present study, several recent publications
have also demonstrated that dipyridamole may have a direct effect
on vascular smooth muscle cell function. Singh et al utilized a
rabbit model to demonstrate both in vivo and in vitro that
dipyridamole can inhibit vascular smooth cell proliferation [23].
Ingerman-Wojenski and Silver also used a rabbit model to
demonstrate that dipyridamole can inhibit intimal vascular
smooth muscle cell proliferation in vivo [42]. In contrast, Grun-
wald and Haudenschild could not demonstrate an effect of
dipyridamole alone in affecting vascular smooth muscle cell
migration in a rat model, although a combination of aspirin and
dipyridamole did affect VSMC migration [43]. The present study
extends these previous results by specifically examining the effects
of dipryidamole on vascular growth factor-induced smooth muscle
cell replication.
Dipyridamole is known to modify several biochemical pathways
including inhibition of platelet cAMP phosphodiesterase. Because
cAMP signal transduction pathways can modulate vascular
smooth muscle cell growth, we investigated whether dipyridamole
was exerting its antiproliferative effect in these studies via changes
in intracellular cAMP. In this study, intracellular cAMP levels
were not affected by the addition of dipyridamole at concentra-
tions effective in inhibiting VSMC proliferation. Furthermore,
while the addition of dibutyryl cAMP did diminish PDGF-induced
VSMC proliferation, the level of inhibition was substantially less
than that seen with dipyridamole. These results suggest that the
biologic effects of dipyridamole on vascular smooth muscle cell
proliferation are at most only partially mediated via changes in
cAMP metabolism. However, because there may be more than
one pool of cAMP in VSMC, these studies have not completely
eliminated the possibility that dipyridamole acts directly on a
functional cAMP pooi without affecting total intracellular cAMP
levels.
In summary, we have demonstrated that dipyridamole pro-
foundly inhibits both PDGF and bFGF induced VSMC prolifer-
ation. These results are not caused by a toxic effect of dipyridam-
ole, as VSMC are still responsive to growth factors after
dipyridamole is removed from the culture. These results are also
obtained at dipyridamole concentrations comparable to therapeu-
tic plasma concentrations with conventional doses. The direct
effect of dipyridamole on VSMC proliferation is to date the best
explanation available to explain its clinical effect in decreasing
ePTFE graft thrombosis in hemodialysis patients. Further re-
search will be required to elucidate the mechanisms by which
dipryidamole inhibits VSMC proliferation.
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